Építés alatt – nem éles oldal
Belépés
Visszavonva1/2. fázis

Adoptive Treatment of Advanced Hepatocellular Carcinoma With Allogeneic γδ-T Cells

A legfontosabb adatok

Ki végzi
Guangdong GD Kongming Biotech LLC
Hol
Kína1 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Visszavonva
Fázis
1/2. fázis
Kezdés
2021. nov. 1.
Befejezés
2024. okt. 31.
A vizsgálat típusa
Beavatkozással járó
A vizsgált kezelések
  • GDKM-100 injection
A regiszteradat frissítve
2023. január 18.
Miért állt le
COVID1-19 pandemic

Ki vehet részt

Életkor
18 év – 75 év
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 15 feltétel megnézéseKevesebb

Ki vehet részt

  • Age is 18-75 years old, and gender is unlimited
  • HCC was confirmed by pathological or clinical examination
  • Patients with stage CNLCIII, IV primary HCC who are receiving second-line treatment / unable to receive existing treatments, or CNLCI and II of primary HCC patients who are unable to receive existing treatments
  • Male subjects with partner women of childbearing age must have reliable, effective methods of contraception starting from the signing of the informed consent form until 120 days after the last dose of the study drug. Male subjects with a pregnant spouse must use condoms without other contraceptive methods
  • Participants volunteered to join the study, signed an informed consent, had good compliance, and cooperated with the follow-up

Ki nem vehet részt

  • Accept other cellular or immune clinical experiments within 8 weeks before enrollment
  • Hormone use during cell therapy: dexamethasone dose exceeds 2mg / day during immunotherapy
  • Gastrointestinal bleeding, refractory ascites, hepatic encephalopathy, or hepatorenal syndrome
  • Immunological deficiency, a known immunosuppressive disease or HIV
  • Active infection, unexplained fever
  • Serious or unstable heart, lung, kidney and hematopoietic system diseases
  • Autoimmune diseases, such as rheumatoid arthritis
  • Neurological diseases, diffuse leptomeningeal diseases; combined with neurodegenerative diseases
  • The subject had a known history of psychotropic substance abuse or drug use; he had stopped drinking Patients can be enrolled; 11 In the judgment of the investigator, the subject has other factors that may cause the forced termination of the study, such as other serious diseases or serious abnormal laboratory examination or other family or social factors that will affect the subject's safety of the subject, or the collection of trial data and samples
  • Pregnant or lactating women

Hol van ez a vizsgálat?

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

Brief Summary: In this study, effects of γδ T cells on Advanced hepatocyte carcinoma The goal of this clinical trial is to learn about effects of allogeneic γδ T therapy in advanced hepatocyte carcinoma patients.

A teljes eredeti leírásKevesebb

The main question it aims to answer is:Will advanced hepatocyte carcinoma patients be benefit from allogeneic γδ T therapy? Participants will received GDKM-100injection (allo-γδ T Cells) Infusion every two weeks.

A vizsgálat csoportja

  • GDKM-100 injectionA vizsgált kezelés

    In this trial, the patients will receive multiple high-activity γδ T cell immunotherapies.The trial is divided into two parts: Part 1 is a multiple-dose escalation trial consisting of 3 dose groups (2×10\^8 cells/person, 5×10\^8 cells/person, 10×10\^8 cells/person at 1-3 infusion, 4-6 infusion and 7-9 infusion), with 9 patients planned to be enrolled. Part 2 is a single dose trial in which doctor and the PI evaluates whether to give the rest patients to receive the 10×10\^8 cells/person infusions based on available safety data. The check indexes are CT scan,intestinal flora detection and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Clinical Study on Adoptive Treatment of Advanced Hepatocellular Carcinoma With Allogeneic γδ-T Cells
A regiszteradat frissítve
2023. január 18.